Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Strategies

Set Alert for Pricing Strategies

Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary

Months after obtaining the first US FDA designation of interchangeability, for its Semglee biosimilar to Sanofi’s Lantus, Viatris has seen a return on its investment, with the biosimilar scooping preferred status on one of the largest national formularies in the US.

Biosimilars Commercial

Will All US Biosimilar mAbs Be Interchangeable In The Long Run?

As Boehringer Ingelheim’s Cyltezo has become the second-ever interchangeable biosimilar approved by the US FDA – as well as the first monoclonal antibody to garner the designation and offering the first published data from a switching trial to support interchangeability – the debate around the potential impact for interchangeable products in the keenly-watched adalimumab space and beyond continues to grow.

Biosimilars Regulation

Indoramin Increase Tops UK Rises In September

Benign prostatic hyperplasia treatment indoramin topped the UK’s steepest generic price rises in September with an average price that more than trebled, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab

Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.

Biosimilars Strategy

Sandoz, Apotex And Taro Strike Civil Settlements On Price-Fixing

Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.

Legal Issues Deals

New Zealand’s Pharmac Mulls Amgevita Listing

New Zealand’s Pharmac pharmaceutical management agency is considering funding Amgen’s Amgevita adalimumab biosimilar rather than the Humira reference brand from early 2022.

Biosimilars Reimbursement

AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases

The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”

Policy Pricing Debate

Timolol Tops UK Price Rises In August

Timolol eye drops saw their prices leap in August while sildenafil’s slide saw prices cut in half, according to the latest UK generics pricing figures from WaveData.

Market Intelligence Pricing Strategies

UK Sees Several Triple-Digit Price Rises In July

Ivabradine, lercanidipine, donepezil and aspirin led the steepest price rises seen for UK generics in July 2021, with all of these molecules experiencing triple-digit average increases in certain presentations, according to WaveData.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register